JP2019533645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533645A5
JP2019533645A5 JP2019514781A JP2019514781A JP2019533645A5 JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5 JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5
Authority
JP
Japan
Prior art keywords
protein
agents
protein nanocage
nanocage
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052079 external-priority patent/WO2018053434A1/en
Publication of JP2019533645A publication Critical patent/JP2019533645A/ja
Publication of JP2019533645A5 publication Critical patent/JP2019533645A5/ja
Pending legal-status Critical Current

Links

JP2019514781A 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ Pending JP2019533645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395852P 2016-09-16 2016-09-16
US62/395,852 2016-09-16
PCT/US2017/052079 WO2018053434A1 (en) 2016-09-16 2017-09-18 Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Publications (2)

Publication Number Publication Date
JP2019533645A JP2019533645A (ja) 2019-11-21
JP2019533645A5 true JP2019533645A5 (https=) 2020-10-08

Family

ID=60002019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514781A Pending JP2019533645A (ja) 2016-09-16 2017-09-18 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ

Country Status (4)

Country Link
US (1) US11090391B2 (https=)
EP (1) EP3512563A1 (https=)
JP (1) JP2019533645A (https=)
WO (1) WO2018053434A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503704A (zh) * 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
WO2019222400A2 (en) * 2018-05-15 2019-11-21 Dnalite Therapeutics, Inc. Mucus-penetrating peptides, delivery vehicles and methods of therapy
EP3863610A4 (en) * 2018-10-10 2023-03-29 University of Washington High-polymer-density bioconjugate compositions and related methods
WO2020180144A1 (ko) * 2019-03-07 2020-09-10 경북대학교 산학협력단 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
JP7600993B2 (ja) * 2019-09-05 2024-12-17 味の素株式会社 ペプチド内包フェリチン
US20240150417A1 (en) * 2019-11-01 2024-05-09 Cellemedy Co.,Ltd Disease antigen-fused protein, and use thereof
EP4053153A4 (en) * 2019-11-01 2023-12-20 Cellemedy Co., Ltd PROTEIN FUSED WITH A MOLECULE CAPABLE OF BINDING AN IMMUNE CHECKPOINT MOLECULE AND USE THEREOF
JP7541390B2 (ja) * 2019-11-01 2024-08-28 セレメディー カンパニー，リミテッド 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
KR102658825B1 (ko) * 2020-10-23 2024-04-19 경북대학교 산학협력단 Pd-l1 결합 펩타이드 1을 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN112972421B (zh) * 2021-02-26 2022-04-08 清华大学 基于多正电荷蛋白的纳米药物系统、其制备方法及应用
CN115160559B (zh) * 2021-04-02 2024-02-02 杭州宜生医药科技发展有限公司 一种peg化雷帕霉素化合物及其制备方法与应用
WO2024228598A1 (ko) * 2023-05-04 2024-11-07 경북대학교 산학협력단 Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도
CN119326734B (zh) * 2024-12-17 2025-06-06 浙江大学 一种铁蛋白纳米颗粒及其药物递送系统的组装方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6699475B1 (en) 1987-09-02 2004-03-02 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
KR920003787B1 (ko) 1990-03-05 1992-05-14 한국과학기술 연구원 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
WO2000011947A1 (en) 1998-08-28 2000-03-09 Uropath Pty. Ltd. Method of diagnosis of prostate cancer
DE60028361T2 (de) 1999-02-26 2007-05-10 Pacific Northwest Research Institute, Seattle Verfahren und zusammensetzungen zur karzinomdiagnose
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN101355965A (zh) 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
WO2007114946A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Acid-sensitive linkers for drug delivery
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
WO2010029947A1 (ja) * 2008-09-09 2010-03-18 国立大学法人京都大学 造影剤組成物及びその製造方法
BR112013021732B1 (pt) * 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
US20140329913A1 (en) * 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
CA2921493A1 (en) 2012-08-21 2014-02-27 Brown University Ferritin-based tumor targeting agent, and imaging and treatment methods
US11202820B2 (en) * 2014-09-25 2021-12-21 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages

Similar Documents

Publication Publication Date Title
JP2019533645A5 (https=)
JP2025066807A (ja) 生体直交型組成物
AU2018250312B2 (en) Bioorthogonal compositions
CN103796684B (zh) 大分子
US20180085321A1 (en) Solid nanoparticle with inorganic coating
CA3202226A1 (en) Compositions of peptide inhibitors of interleukin-23 receptor
JP2010513526A5 (https=)
JP7102005B2 (ja) 改善されたハイブリッドテロデンドリマー
JP2012532185A5 (https=)
WO2016206540A1 (zh) 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
JP2008529539A5 (https=)
JP2015519330A5 (https=)
JP2013512889A5 (https=)
JP2009500431A5 (https=)
US20240335548A1 (en) Macromolecules
JP2017119721A (ja) 併用療法用ナノ粒子
EP3883934A1 (en) Therapeutic dendrimer
JP2016509586A5 (https=)
JP2021523912A5 (https=)
CN116133693B (zh) 载药的大分子及其制备方法
JP2023500602A (ja) ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。
JP2026500527A (ja) 脂質化合物ならびにその製造方法及び使用方法
CN111373246A (zh) 包括硼替佐米的聚合物纳米颗粒
US12611461B2 (en) Bioorthogonal compositions
US20250049936A1 (en) Bioorthogonal compositions